BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Accredo Health Inc. (ACDO) Comments On CMS Remodulin Reimbursement Change And Increases Fiscal 2005 Earnings Per Share Estimate


10/19/2005 5:12:03 PM

Accredo Health, Incorporated (NASDAQ:ACDO) today reported that the Centers for Medicare and Medicaid Services (CMS) instructed the Durable Medical Equipment Regional Carriers (DMERCs) to adjust the 2004 pricing allowance for Remodulin(R) (Treprostinil) to $61.75 per milligram. The adjustment is retroactive to January 1, 2004, and allows Medicare DMERC providers to rebill all relevant claims that were reimbursed at reduced rates during that period. Since January 1, 2004, the effective date of the Medicare Prescription Drug, Improvement and Modernization Act of 2003 (MMA), the DMERCs established payment rates for the 10 mg Remodulin(R) vial size at rates that are below the Company's acquisition cost of the drugs. In addition, one regional DMERC was paying all Remodulin(R) vial sizes at the same rate per milligram as that of the 10 mg vial, thus reducing the Company's reimbursement for all Medicare recipients of Remodulin(R) in that region.

Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES